JZP441 / Sumitomo Pharma, Jazz - LARVOL DELTA

A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1 (clinicaltrials.gov) - P1 | N=8 | Recruiting | Sponsor: Jazz Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Narcolepsy • Sleep Disorder

A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1 (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: Jazz Pharmaceuticals

New P1 trial • Narcolepsy • Sleep Disorder

A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy Participants (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Jazz Pharmaceuticals | Active, not recruiting ➔ Completed | N=98 ➔ 24

Enrollment change • Trial completion

A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy Participants (clinicaltrials.gov) - P1 | N=105 | Completed | Sponsor: Jazz Pharmaceuticals | Active, not recruiting ➔ Completed | Trial completion date: Oct 2024 ➔ Nov 2023 | Trial primary completion date: Oct 2024 ➔ Nov 2023

Trial completion • Trial completion date • Trial primary completion date

A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy Participants (clinicaltrials.gov) - P1 | N=98 | Active, not recruiting | Sponsor: Jazz Pharmaceuticals | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2023 ➔ Oct 2024 | Trial primary completion date: Oct 2023 ➔ Oct 2024

Enrollment closed • Trial completion date • Trial primary completion date

A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy Participants (clinicaltrials.gov) - P1 | N=132 | Active, not recruiting | Sponsor: Jazz Pharmaceuticals | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2023 ➔ Oct 2024 | Trial primary completion date: Dec 2023 ➔ Oct 2024

Enrollment closed • Trial completion date • Trial primary completion date

A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy Participants (clinicaltrials.gov) - P1 | N=132 | Recruiting | Sponsor: Jazz Pharmaceuticals | Trial completion date: Apr 2023 ➔ Dec 2023 | Trial primary completion date: Apr 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date

A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy Participants (clinicaltrials.gov) - P1 | N=98 | Recruiting | Sponsor: Jazz Pharmaceuticals

New P1 trial

A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy Participants (clinicaltrials.gov) - P1 | N=132 | Recruiting | Sponsor: Jazz Pharmaceuticals

New P1 trial